BlackRock Fund Advisors recently announced the acquisition of new stake in TransMedics Group Inc. (NASDAQ:TMDX). The institutional investor has increased its shareholding in the Healthcare company by 14.79% to 1.99 million shares with purchase of 0.26 million shares. This fresh investment now brings its stake to 6.23% valued currently at $122.75 million. In addition, The Vanguard Group, Inc. raised its holdings by 0.2 million to 1.57 million shares. And Driehaus Capital Management LLC has lifted its position by 62.08% or 0.38 million shares – to 1.0 million shares.
With over 0.29 million TransMedics Group Inc. (TMDX) shares trading Friday and a closing price of $60.90 on the day, the dollar volume was approximately $17.45 million. The shares have shown a positive half year performance of 82.34% and its price on 01/13/23 gained nearly 2.15%. Currently, there are 31.92M common shares owned by the public and among those 30.68M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for TMDX have a consensus price objective of $64.60. The analysts have set the share’s price value over the next 12 months at a high of $70.00 and a low of $55.00. The average price target is 5.73% above its recent price level and a downside to the estimated low will see the stock lose -10.73% over that period. But an upside of 13.0% will see the stock hit the forecast high price target while median target price for the stock is $67.00.
Insiders at the company have transacted a total of 109 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 48 of these insider trades were purchases, accounting for 235,478 shares. Insider sales of the common stock occurred on 61 occasions, with total insider shares sold totaling 471,113 shares.
The top 3 mutual fund holders in TransMedics Group Inc. are Delaware Small Cap Core Fund, Fidelity Advisor Series I -Growth, and CS Invt. Fds. 2 -. Delaware Small Cap Core Fund owns 1.5 million shares of the company’s stock, all valued at over $92.86 million. The company sold -0.19 million shares recently to bring their total holdings to about 4.71% of the shares outstanding. Fidelity Advisor Series I -Growth sold -0.21 million shares to see its total holdings shrink to 1.22 million shares valued at over $75.31 million and representing 3.82% of the shares outstanding. CS Invt. Fds. 2 – sold 70000.0 shares to bring its total holdings to over 0.98 million shares at a value of $60.49 million. CS Invt. Fds. 2 – now owns shares totaling to 3.07% of the shares outstanding.
Shares of TransMedics Group Inc. (NASDAQ: TMDX) opened at $59.29, down -$0.33 from a prior closing price of $59.62. However, the script later moved the day high at 61.34, up 2.15%. The company’s stock has a 5-day price change of 9.47% and 48.65% over the past three months. TMDX shares are trading -1.33% year to date (YTD), with the 12-month market performance up to 260.36% higher. It has a 12-month low price of $10.00 and touched a high of $64.36 over the same period. TMDX has an average intraday trading volume of 342.64K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.92%, 5.80%, and 46.52% respectively.
Institutional ownership of TransMedics Group Inc. (NASDAQ: TMDX) shares accounts for 94.80% of the company’s 31.92M shares outstanding. Mutual fund holders own 38.97%, while other institutional holders and individual stakeholders account for 51.43% and 19.76% respectively.
It has a market capitalization of $1.90B and a beta (3y monthly) value of 1.57. The earnings-per-share (ttm) stands at -$1.49. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.67% over the week and 5.71% over the month.
Analysts forecast that TransMedics Group Inc. (TMDX) will achieve an EPS of -$0.41 for the current quarter, -$0.38 for the next quarter and -$1.18 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.47 while analysts give the company a high EPS estimate of -$0.35. Comparatively, EPS for the current quarter was -$0.47 a year ago. Earnings per share for the fiscal year are expected to decrease by -37.60%, and 18.80% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate TransMedics Group Inc. (TMDX) as a “Strong Buy” at a consensus score of 1.80. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 1 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the TMDX, a number of firms have released research notes about the stock. JP Morgan stated their Overweight rating for the stock in a research note on August 02, 2022, with the firm’s price target at $48. JP Morgan coverage for the TransMedics Group Inc. (TMDX) stock in a research note released on October 08, 2020 offered a Neutral rating with a price target of $15. JP Morgan on their part issued Overweight rating on May 28, 2019.